A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Inclusion Criteria

• •Male or female participants must be ≥ 18 years old
• •Mean sitting systolic blood pressure on automated office blood pressure measurement ≥ 140 mmHg and \< 170 mmHg at Screening
• •Fulfil at least 1 of the following 2 criteria:
• •1. uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
• •2. rHTN subpopulation: have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
• •Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening
• •Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening
• •Randomisation Criterion:
• •Sitting systolic blood pressure on attended automated office blood pressure measurement of ≥ 135 mmHg at the Baseline Visit